Results 81 to 90 of about 4,708,479 (153)
Semiparametric Bayesian Modeling of Multivariate Average Bioequivalence [PDF]
Bioequivalence trials are usually conducted to compare two or more formulations of a drug. Simultaneous assessment of bioequivalence on multiple endpoints is called multivariate bioequivalence.
Ghosh, Pulak, Dr., Gonen, Mithat
core +1 more source
Tofacitinib is a potent, selective inhibitor of the Janus kinase (JAK) family of kinases with a high degree of selectivity within the human genome's set of protein kinases. Currently approved formulations for tofacitinib citrate are immediate‐release (IR) tablets, modified‐release (MR) tablets, and IR solution.
Vivek Purohit +10 more
openaire +2 more sources
The bioequivalence (BE) of highly variable drugs is a complex issue in the pharmaceutical industry. The impact of this variability can significantly affect the required sample size and statistical power.
Dimitris Papadopoulos +2 more
doaj +1 more source
PRT to predict pharmacokinetic profiles as part of a bioequivalence study of the drug deferasirox
Introduction. Deferasirox is a complexing drug and belongs to class II according to the biopharmaceutical classification system (BCS), has acidic properties and belongs to subclass “a” (acid).
A. V. Suvorova +6 more
doaj +1 more source
Bioequivalence: The Regulatory Career of a Pharmaceutical Concept [PDF]
Generic drugs cannot be marketed without regulatory and clinical demonstration of "bioequivalence." The authors argue that the concept of "bioequivalence" is a joint regulatory and scientific creation, not purely a technical concept, and not purely a ...
Tobbell, Dominique A., Carpenter, Daniel
core +1 more source
Raymond R Tjandrawinata,1 Effi Setiawati,2 Danang Agung Yunaidi,2 Ronal Simanjuntak,2 Iwan Dwi Santoso,2 Liana W Susanto1 1Dexa Laboratories of Biomolecular Sciences (DLBS), Cikarang, Indonesia; 2Bioavailability and Bioequivalence Laboratory, PT Equilab ...
Tjandrawinata RR +5 more
core
Connections between average and individual bioequivalence
As pointed out by Anderson and Hauck and others, average bioequivalence does not guarantee that a patient, being on a drug, may switch to a different formulation. The consideration of individual bioequivalence was therefore suggested.
Munk, Axel
core +1 more source
The aim of the present study was to assess the accuracy of the PBPK model in predicting the pharmacokinetic behavior of weakly acidic BCS class II drugs in humans through a multipronged approach of in vitro dissolution, in vivo studies, and in silico simulations.
Chenxia, Bai +4 more
openaire +2 more sources
The vaginal route of administration enables convenient local and systemic drug delivery with the avoidance of hepatic first-pass metabolism. Considering the clinical advantages of vaginal delivery, development of physiologically based pharmacokinetic (PBPK) models of vaginal absorption to inform drug and formulation development is deemed valuable.
Kanika Thakur +8 more
openaire +3 more sources
Introduction. Sorafenib is an antineoplastic drug belonging to class IIc according to the biopharmaceutical classification system (BCS) due to the presence of both acidic and basic properties.
A. V. Suvorova +6 more
doaj +1 more source

